In vitro chemosensitivity test of malignant gliomas: clinical relevance of test results independent of adjuvant chemotherapy.
Tumor specimens of malignant human gliomas were processed in a colony forming assay (CFA, n = 70) and a metabolic test system (MTT-test, n = 49) for in-vitro chemosensitivity testing. The clinical data as well as the complete follow-up of these patients were obtained until their death or at least 2 years of survival. By means of multivariate statistical analysis we demonstrate that both test systems are not influenced by biometrical data of the patient of histopathological parameters of the tumor. According to the COX regression model the results of both assays are per se no prognostic factor when regarded independently of additional treatment. However, in 33 patients treated with either ACNU or BCNU, a prospective correlative trial clearly demonstrates a predictive value of the CFA in adjuvant chemotherapy of gliomas.
Tonn
J C
JC
Department of Neurosurgery, University of Würzburg, Germany.
Schachenmayr
W
W
Kraemer
H P
HP
D002330:Carmustine / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000494:pharmacology / Q000627:therapeutic use; D015996:Survival Rate; D014410:Tumor Stem Cell Assay
D015376:Nimustine; D002330:Carmustine